Dr PennyStock Free Forums
January 22, 2018, 04:34:26 PM *
Welcome, Guest. Please login or register.

Login with username, password and session length
News:
   Home   Help Search Login Register  
Pages: [1] 2   Go Down
  Print  
Author Topic: AEZS - AEterna Zentaris Inc - NASDAQ  (Read 6372 times)
0 Members and 1 Guest are viewing this topic.
Sixshooter
Jr. Member
**
Offline Offline

Gender: Male
Posts: 97



« on: April 02, 2012, 12:35:53 PM »


Daily Chart:  http://stockcharts.com/h-sc/ui?s=AEZS&p=D&b=5&g=0&id=p84825812831

Weekly Chart:  http://stockcharts.com/h-sc/ui?s=AEZS&p=W&b=5&g=0&id=p78513451645

News:  http://finance.yahoo.com/q/h?s=AEZS+Headlines

Business Summary:  Aeterna Zentaris Inc., a late-stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in the United States, Switzerland, and Japan. It provides Cetrotide, a luteinizing hormone-releasing hormone (LHRH) antagonist treatment for in vitro fertilization. The company's product pipeline includes Perifosine, an oral anticancer treatment that inhibits Akt activation in the PI3K pathway, which is in Phase III studies for the treatment of colorectal cancer and multiple myeloma, as well as in Phase II studies for the treatment of other cancers; and AEZS-108, a targeted cytotoxic peptide conjugate in Phase II studies for the treatment of endometrial, ovarian, prostate, and bladder cancer.

It is also developing AEZS-130, an oral diagnostic test in Phase III trial for adult growth hormone deficiency, as well as in Phase I trial for the treatment of severe chronic diseases, such as cancer induced cachexia; and AEZS-112, which is in Phase I clinical trial for the treatment of solid tumors. In addition, its product candidates in preclinical development include AEZS-115 for the treatment of multiple cancers, benign prostatic hyperplasia (BPH), and endometriosis; AEZS-129, 131, and 132 Erk and PI3K inhibitors for oncology; AEZS-120, a vaccine for prostate cancer and melanoma; AEZS-127 for the treatment of multiple cancers; AEZS-123 to treat obesity and related pathologies; and AEZS-137 for the treatment of solid tumors.

Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.

Company Website: http://www.aezsinc.com/en/index.php
Logged

The safe way to double your money is to fold it over once and put it in your pocket. - Kin Hubbard
PaulPaulPaulPaul
Jr. Member
**
Offline Offline

Gender: Male
Posts: 84



« Reply #1 on: April 04, 2012, 07:13:51 PM »

This had a big gap downwards.  Right now it is sitting at the .75 support area.  I think it is a watch for now so we can see if it holds this support. 

http://stockcharts.com/h-sc/ui?s=AEZS&p=D&b=5&g=0&id=p84825812831
Logged
justonian
Hero Member
*****
Offline Offline

Gender: Male
Posts: 576


« Reply #2 on: April 05, 2012, 09:58:38 AM »

OUCH, gotta feel bad for the cats in there a few days ago. 
Logged
PaulPaulPaulPaul
Jr. Member
**
Offline Offline

Gender: Male
Posts: 84



« Reply #3 on: April 05, 2012, 03:59:05 PM »

We will have to see if it can push past that resistance at .82ish next week.  If it looks like it will and gaining momentum, I will probably hop in.
Logged
PaulPaulPaulPaul
Jr. Member
**
Offline Offline

Gender: Male
Posts: 84



« Reply #4 on: April 09, 2012, 06:18:53 PM »

Looks like it gapped up at the open, but filled the gap pretty quickly.  The RSI 30 mark provided some resistance for it today.  We will see if it can push through it or not!  It did have a nice bounce off .77.
Logged
Sixshooter
Jr. Member
**
Offline Offline

Gender: Male
Posts: 97



« Reply #5 on: April 30, 2012, 10:39:41 AM »

Scared with all the bad moves i've been making lately, but jumped in this one...
Logged

The safe way to double your money is to fold it over once and put it in your pocket. - Kin Hubbard
Dr PennyStock
Administrator
*****
Online Online

Gender: Male
Posts: 26757



WWW
« Reply #6 on: April 30, 2012, 11:15:32 AM »

It doesn't look bad.
Logged

Dr PennyStock
softballdaddy
Sr. Member
****
Offline Offline

Gender: Male
Posts: 403



« Reply #7 on: September 13, 2012, 04:53:00 PM »

 AEZS Looks like it is in a breakout
Logged

Life is tough, and it is tougher if you are stupid...John Wayne
Vegas
Gold Member
******
Offline Offline

Gender: Male
Posts: 4283



« Reply #8 on: September 13, 2012, 06:07:26 PM »

AEZS Looks like it is in a breakout

Yep... Too bad it is so oversold... Always good to see ya SBD...
Logged

♦♦♦ Give me control of a nations money supply, and I care not who makes it’s laws... Mater Amschel Rothschild ♦♦♦
softballdaddy
Sr. Member
****
Offline Offline

Gender: Male
Posts: 403



« Reply #9 on: September 13, 2012, 06:39:01 PM »

Thanks pinky  Cheesy

Good to see you.
Logged

Life is tough, and it is tougher if you are stupid...John Wayne
justonian
Hero Member
*****
Offline Offline

Gender: Male
Posts: 576


« Reply #10 on: September 14, 2012, 09:42:13 AM »

Thanks pinky  Cheesy

Good to see you.

Does that make you the brain?  Smiley   Good to cya sbd, you gave a couple of pointers way back that helped me out, much appreciated.
Logged
choc101
Full Member
***
Offline Offline

Gender: Male
Posts: 200



« Reply #11 on: September 20, 2012, 05:08:57 PM »

Nice movement the last few days on this one. These Nasdaq bio's have been doing well lately. Might be worth keeping an eye on them.
Logged
Anthony
Sr. Member
****
Offline Offline

Gender: Male
Posts: 326


« Reply #12 on: September 25, 2012, 08:17:49 AM »

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company") today announced that the European Patent Office ("EPO") has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February19, 2007, the patent (EP #1984744 B1) titled, "Methods and Kits to Diagnose Growth Hormone Deficiency", was effective as of September 19, 2012, following its announcement in the European Patent Bulletin, and will expire on February 19, 2027. A similar patent has already been granted in the U.S.

Juergen Engel, Ph.D., Aeterna Zentaris President and CEO, commented, "This patent in Europe, along with the one already granted in the U.S., are key elements to ensure the protection of AEZS-130 for the diagnosis of GHD, in the world's two largest markets. We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD".

About AGHD (Adult Growth Hormone Deficiency)

AGHD affects 35,000 adult Americans, with 6,000 new adult patients diagnosed each year. Growth hormone not only plays an important role in growth from childhood to adulthood, but helps promote good health throughout life. AGHD is usually characterized by low energy levels, decreased strength and exercise tolerance, increased weight or difficulty losing weight, emotional changes, anxiety and impaired sleep.

About AEZS-130

AEZS-130, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The Company has completed a Phase 3 trial for use as an oral diagnostic test for AGHD. AEZS-130 has been granted orphan drug designation by the FDA for use in this indication. AEZS-130 is also in a Phase 2A trial as a treatment for cancer-induced cachexia. Aeterna Zentaris owns the worldwide rights to AEZS-130.

Logged

NO GUTS,NO GLORY!!
Anthony
Sr. Member
****
Offline Offline

Gender: Male
Posts: 326


« Reply #13 on: November 29, 2012, 04:32:49 PM »

It looks like this POS is picking up some steam,pun intended.LOL

Lets see if it holds.
Logged

NO GUTS,NO GLORY!!
Dr PennyStock
Administrator
*****
Online Online

Gender: Male
Posts: 26757



WWW
« Reply #14 on: November 30, 2012, 09:41:36 AM »

It has resistance at 2.37 and stopped yesterday at 2.35, may make a double top here.
Logged

Dr PennyStock
Pages: [1] 2   Go Up
  Print  
 
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.8 | SMF © 2006-2008, Simple Machines LLC | Sitemap Valid XHTML 1.0! Valid CSS!
Page created in 0.105 seconds with 25 queries. (Pretty URLs adds 0.017s, 2q)